Core Viewpoint - First Mining Gold Corp. successfully closed an over-subscribed public offering, raising a total of $12,000,600 through the sale of 66,670,000 units at a price of $0.18 per unit [1][2]. Group 1: Public Offering Details - The public offering consisted of units, each comprising one common share and one-half of a common share purchase warrant, with the warrant allowing the purchase of one common share at $0.27 within 36 months [2]. - The offering was conducted under a prospectus supplement dated July 16, 2025, and the net proceeds will be allocated to advancing the Springpole and Duparquet gold projects, as well as for general working capital [3]. Group 2: Company Overview - First Mining Gold Corp. is advancing two major gold projects in Canada: the Springpole Gold Project, which is in the feasibility study phase, and the Duparquet Gold Project, currently at the PEA stage [5]. - The company also holds interests in other gold projects, including the Cameron Gold Project, Pickle Crow Gold Project, and Hope Brook Gold Project [5].

Nasdaq-listed GameSquare announced the completion of a public offering of approximately $70 million and stated that the majority of the proceeds will be used to expand its ETH holdings, aiming to become one of the largest publicly listed holders of ETH. https://t.co/05HFgwX7Wq ...

Company Overview - LiveOne is a creator-first music, entertainment, and technology platform headquartered in Los Angeles, CA, focused on delivering premium experiences and content worldwide through memberships and live and virtual events [5] - The company's subsidiaries include Slacker, PodcastOne, PPVOne, Custom Personalization Solutions, LiveXLive, DayOne Music Publishing, Drumify, and Splitmind [5] Public Offering Announcement - LiveOne announced the commencement of an underwritten public offering of shares of its common stock, subject to market conditions [1] - Lucid Capital Markets is acting as the sole book-running manager for the offering, which is made pursuant to a shelf registration statement filed with the SEC [2] Regulatory Filings - A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website [3]

Core Points - BriaCell Therapeutics Corp. announced a public offering of 12,000,000 units at a price of $1.25 per unit, aiming for gross proceeds of $15 million before expenses [1][3] - Each unit consists of one common share (or a Pre-Funded Warrant) and one Warrant, with the Warrant allowing the purchase of one common share at an exercise price of $1.50, expiring five years from issuance [1][3] - The offering is expected to close on July 16, 2025, subject to customary closing conditions [2] Financial Details - The net proceeds from the offering will be used for working capital, general corporate purposes, and advancing business objectives [3] - The offering is being facilitated by ThinkEquity as the sole placement agent [3] Regulatory Information - A registration statement on Form S-1 was filed with the SEC and became effective on July 15, 2025, with the offering being made only by means of a prospectus [4]

Core Viewpoint - Milestone Pharmaceuticals Inc. has announced a public offering of common shares and warrants, aiming to raise approximately $52.5 million to fund the clinical development and commercialization of its lead drug, etripamil, for treating paroxysmal supraventricular tachycardia (PSVT) [1][2]. Group 1: Offering Details - The public offering includes 31,500,000 common shares and accompanying Series A and Series B common warrants, priced at $1.50 per share and warrant [1]. - Additionally, pre-funded warrants to purchase 3,502,335 common shares are offered at a price of $1.499, which includes accompanying Series A and Series B common warrants [1]. - The offering is expected to close around July 14, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized alongside existing cash to support the clinical development and commercial launch of etripamil for PSVT, as well as for working capital and general corporate purposes [2]. Group 3: Company Background - Milestone Pharmaceuticals is focused on developing and commercializing innovative cardiovascular medicines, with a recent New Drug Application (NDA) submitted to the FDA for etripamil targeting PSVT [5].

Core Viewpoint - Soleno Therapeutics, Inc. has announced a public offering of 2,352,941 shares of common stock priced at $85.00 per share, aiming to raise approximately $200 million before expenses [1][3]. Group 1: Offering Details - The public offering consists of 2,352,941 shares, with an additional 30-day option for underwriters to purchase up to 352,941 more shares at the same price [1]. - The offering is expected to close on or about July 11, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds will primarily fund the commercialization of VYKAT XR, the first approved therapy for hyperphagia in Prader-Willi syndrome, which received FDA approval on March 26, 2025 [3]. - Additional proceeds will support regulatory and market development activities in the EU, further R&D efforts, and general corporate purposes, including working capital and potential acquisitions [3]. Group 3: Underwriters - Goldman Sachs & Co. LLC, Guggenheim Securities, TD Cowen, Cantor, and Oppenheimer & Co. are serving as joint book-running managers for the offering [2]. Group 4: Company Overview - Soleno Therapeutics focuses on developing novel therapeutics for rare diseases, with VYKAT XR being its first commercial product aimed at treating hyperphagia in individuals aged 4 and older with Prader-Willi syndrome [6].

Core Viewpoint - Soleno Therapeutics, Inc. plans to offer and sell $200 million of its common stock in an underwritten public offering, with an additional option for underwriters to purchase up to $30 million more [1][2]. Group 1: Offering Details - The public offering is subject to market conditions, and there is no assurance regarding the completion or terms of the offering [1]. - Goldman Sachs & Co. LLC and Guggenheim Securities are acting as the joint book-running managers for the offering [2]. - The shares will be offered under a registration statement previously filed with the SEC, and a preliminary prospectus will be made available [4]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to fund the commercialization of VYKAT™ XR, the first approved therapy for hyperphagia in Prader-Willi syndrome, which received FDA approval on March 26, 2025 [3]. - Proceeds will also support regulatory and market development activities in the EU, further R&D efforts, and general corporate purposes, including working capital and potential acquisitions [3][6].

Company Overview - Rhythm Pharmaceuticals, Inc. is a global, commercial-stage biopharmaceutical company focused on rare neuroendocrine diseases [1] Proposed Offering - Rhythm announced a proposed public offering of $150 million of its common stock, with an additional option for underwriters to purchase up to $22.5 million of shares [1][2] - The offering is subject to market conditions and customary closing conditions, with no assurance on completion or terms [2] Regulatory Compliance - The offering is made under a shelf registration statement on Form S-3, which became effective on March 2, 2023 [3] - A preliminary prospectus supplement will be filed with the SEC and available on their website [3] Contact Information - Investor relations contact is David Connolly, Head of Investor Relations and Corporate Communications, reachable at 857-264-4280 [6]

Core Viewpoint - Borr Drilling Limited plans to raise $100 million through a public offering of approximately 50 million shares for general corporate purposes [1] Group 1: Offering Details - The offering will be conducted under an effective shelf registration statement filed with the SEC on April 11, 2025 [3] - The offering is expected to include two settlements: 30 million shares on July 7, 2025, and 20 million shares on August 7, 2025, contingent on a special general meeting [4] - Certain officers and directors of the Company, including Mr. Tor Olav Trøim, Mr. Patrick Schorn, and Mr. Bruno Morand, have indicated intentions to purchase shares totaling $11.3 million [5] Group 2: Underwriters - DNB Carnegie, Clarksons Securities, Citigroup, and Goldman Sachs & Co. LLC are the joint bookrunners for the offering [2]

Core Viewpoint - ArriVent BioPharma, Inc. plans to offer and sell $75 million of its common stock and pre-funded warrants, with a potential additional 15% option for underwriters, to support its drug development and general corporate purposes [1][2]. Group 1: Offering Details - The public offering includes $75 million in common stock and pre-funded warrants, with a 30-day option for underwriters to purchase an additional 15% [1]. - Goldman Sachs, Citigroup, and Guggenheim Securities are the joint book-running managers for the offering [2]. - An automatic shelf registration statement was filed with the SEC on February 3, 2025, which became effective upon filing [3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to support activities related to firmonertinib and other pipeline programs, as well as for working capital and general corporate purposes [2]. Group 3: Company Overview - ArriVent is a clinical-stage biopharmaceutical company focused on developing innovative therapies for cancer treatment, with a strong emphasis on its lead candidate, firmonertinib [5].